Trade-Named Analogs
N-Acetylated and C-Amidated Dual-Terminus Modified Bioregulator Analogs
A class of seven novel acetylated and amidated dual-terminus modifications of the native bioregulator peptides, developed by Atumnus and protected under a proprietary, patent-pending platform.
Structural and nomenclature data.
- Sequence
- Seven proprietary bioregulator designations: Telogenix, Vasogenix, Dermogenix, Cortigenix, Thymogenix, Lymphogenix, Gonadogenix
- Native MW
- Not applicable (modified class, not a single native compound)
- Khavinson Designation
- Novel Atumnus class; no Khavinson trade name (Khavinson published the native sequences)
- INCI Name
- Modified analog forms; INCI nomenclature pending.
- Modified Analog
- The class itself
- Primary Research Domain
- Same domains as the corresponding native peptides, with extended plasma half-life and enzymatic stability.
Public-domain native form and patent-pending analog.
Native form. The native peptide sequences are public-domain prior science. Atumnus holds patent-pending coverage on its proprietary modified analog forms.
Modified analog form. The acetylated and amidated dual-terminus modification — The class itself — is part of a class of novel compounds developed by Atumnus and protected under a proprietary, patent-pending platform. The N-terminal acetylation and C-terminal amidation are intended to extend plasma half-life and enzymatic stability relative to the native peptide.
Peer-reviewed scientific archive.
The peer-reviewed literature on the trade-named analog portfolio spans research conducted at the St. Petersburg Institute of Bioregulation and Gerontology, the Kirov Military Medical Academy, the Petrov Research Institute of Oncology, the Pavlov Institute of Physiology, the Chita State Medical Academy, and a growing network of international laboratories. The references listed below are reproduced for informational purposes pursuant to Section 5 of the Dietary Supplement Health and Education Act of 1994.
Full PubMed-indexed citation list and reproduced peer-reviewed articles — forthcoming. The complete reference archive will be published as the per-compound literature subsection is populated.
Section 5, DSHEA.
The peer-reviewed scientific publications reproduced or referenced on this page are presented in accordance with Section 5 of the Dietary Supplement Health and Education Act of 1994. The reproductions, where present, are complete; the presentation is balanced; the materials are not promotional of any specific commercial product; and they are physically and architecturally separate from any commercial product surface.
This archive is published by Atumnus Life Sciences, a division of Atumnus LLC, the founding entity of the discipline of endogenic pharmacology, and is independent of the commercial activities of any operating affiliate. The presence of this archive does not constitute a claim about any specific product. No product mentioned on this site is intended to diagnose, treat, cure, or prevent any disease.
Other compounds in the bioregulator class.
The bioregulator class consists of short peptides — di-, tri-, and tetra-peptide sequences — characterized over forty years of pharmaceutical research. Each compound has its own published-literature subsection in this archive.